Posted
U.S. regulators on Monday approved Biogen's aducanumab as the first treatment to attack a likely cause of Alzheimer's disease, despite controversy over whether the clinical evidence proves the drug works. Lisa Bernhard produced this report.
01:16
02:09
02:16
01:10
01:17
01:52
02:48
01:42
01:18
01:06
01:10
01:10
02:53
03:38
01:03
01:56
00:40
01:04
00:15
01:11
01:03
00:37
02:08
02:02
00:23
01:42
00:35
02:13
01:08
02:06
01:01
01:12
00:37
01:11
00:41
00:39
01:11
01:32
00:46
01:38
01:16
00:35
01:08
02:25
01:16
01:19
01:58
01:12
00:35
01:48
02:57
01:36
02:00
01:25
02:44
00:48